Market Context — Why This Technology, Why Now

The global animal health market is experiencing rapid growth, driven by increasing protein consumption and a heightened focus on animal welfare and disease prevention. Regulatory bodies are also pushing for more humane and sustainable practices in animal farming. This creates a critical need for innovative, non-invasive vaccination methods that can be easily scaled, reduce labor dependency, and ensure consistent immune protection across diverse animal populations, from livestock to companion animals.

Key Competitive Advantages
01

Reduces animal stress by over 66% compared to injections, enabling high-volume administration without skilled labor and boosting operational efficiency.

02

Stabilizes antigens by protecting them from gastric acid, ensuring efficient absorption in the digestive tract and maximizing antigen-specific immune response.

03

Secures market dominance with exclusivity until 2044, providing a strong competitive advantage and enabling stable business development and first-mover benefits.

Market Opportunity
Livestock and Aquaculture
$7.5B–$8.5B globally (AI est.)
Increasing demand for meat and rising awareness of animal welfare are driving strong demand for efficient, low-stress vaccine administration, leading to market expansion.
Large-scale livestock producers Aquaculture farm operators Animal feed manufacturers Veterinary pharmaceutical companies
Companion Animal Healthcare
$1.5B–$2.5B globally (AI est.)
With pets increasingly viewed as family members, owner health consciousness is rising, creating a high-value market with strong demand for easy at-home administration.
Pet pharmaceutical companies Pet food and supplement manufacturers Veterinary clinic chains
Zoo and Wildlife Conservation
$50M–$100M globally (AI est.)
For the protection of endangered species, vaccine administration without capture-related stress is critically important, making this a niche market with high social impact.
Wildlife conservation organizations Zoos and animal sanctuaries Specialized veterinary research institutes
IP Defensibility — Why Competitors Can't Replicate This
What This Patent Covers

This patent protects an oral vaccine composition comprising antigens within fibroin-containing nanoparticles. Its strong claims, having overcome eight prior art citations during examination, indicate high novelty and inventiveness, providing a robust and difficult-to-invalidate foundation for long-term competitive advantage.

Competitive White Space

This patent focuses on fibroin nanoparticles for oral animal vaccines. Licensees could explore non-fibroin based oral delivery systems, human-specific oral vaccines, or using fibroin nanoparticles for non-antigenic therapeutic agents.

Economic Impact
~$800K/year estimated operational cost reduction per facility (est.)
estimated ROI · USD · AI analysis
ROI Calculation Logic

For large-scale livestock and aquaculture facilities, injecting vaccines into 1 million animals annually at an estimated cost of $0.80/animal (AI est.) for injection and labor totals $800K/year (AI est.). This oral vaccine technology could reduce these administration costs to near zero, yielding an estimated annual operational cost reduction of ~$800K (AI est.). Additional benefits include improved animal welfare and disease prevention.

Speed to Market
3× faster than in-house development
This technology has completed fundamental research by a national R&D institution, with established mechanisms for antigen protection by fibroin nanoparticles and oral immune induction. This allows adopting companies to significantly shorten initial R&D, focusing instead on validation and optimization for their specific products. Extensive prior research on fibroin biocompatibility further reduces safety evaluation hurdles, potentially accelerating market entry by approximately 3.5 years.
Competitive Positioning

X: Administration Efficiency and Simplicity
Y: Immune Efficacy Stability and Durability

Business Models & Applications
🤝 Technology Licensing
A model to generate royalty revenue by licensing the patent rights for this technology to existing animal vaccine or feed manufacturers.
🔬 Joint Development & OEM
A model to combine a licensee's antigen technology with this patent to co-develop oral vaccines for specific animal species, aiming for revenue through OEM supply after commercialization.
🚀 In-house Brand Product Development
A model to develop, manufacture, and sell proprietary fibroin nanoparticle oral vaccines based on this technology, establishing a brand as a high-value product in the market.
Adjacent Application Opportunities
💊 Pharmaceuticals & Drug Delivery
Oral Biopharmaceuticals for Human Use
Fibroin nanoparticles' ability to protect antigens and enhance gastrointestinal absorption could apply to oral drug delivery for human peptide, protein, or nucleic acid therapies. This could open new markets for non-invasive treatments, potentially improving patient compliance by over 50%.
🍎 Food & Nutritional Supplements
Immune-Boosting Supplements
Leveraging fibroin nanoparticle technology, functional foods and supplements could deliver specific immune-boosting compounds or nutrients stably to the digestive tract. This could create high-value products in pet food and health food sectors, potentially increasing nutrient bioavailability by 30-50%.
🧪 Research Reagents & Tools
Enhanced Cell Delivery Kits
This technology could be developed into research reagents for efficient intracellular delivery of antigens or genes. It could provide new experimental tools for in vitro immune cell research and fields requiring improved gene transfection efficiency, potentially boosting delivery rates by 2-3x.
Integration Roadmap — Estimated 24-Month Deployment
Technology Validation & Prototype Development
Duration: 6 months
Optimize fibroin nanoparticles for the licensee's existing antigens. Conduct small-scale stability and efficacy evaluations to develop a prototype composition.
Pre-clinical Trials & Mass Production Review
Duration: 12 months
Conduct pre-clinical trials for safety and immune induction efficacy in target animal species. Simultaneously, optimize fibroin nanoparticle mass production processes and establish quality control systems.
Regulatory Approval & Market Launch
Duration: 6 months
Prepare and submit applications for regulatory approval in relevant countries. After approval, establish manufacturing and sales systems to launch the product into the market.
Technical Feasibility
The patent claims clearly define the composition of antigen and fibroin-containing nanoparticles, and their manufacturing method is presumed to be adaptable from existing nanoparticle production technologies. Integration into existing vaccine or feed additive manufacturing lines could be relatively straightforward by adding a nanoparticle preparation step, potentially enabling adoption with minimal large-scale capital investment.
Success Scenario
Implementing this technology could allow livestock farmers and pet owners to easily administer vaccines by mixing them into daily feed or water, without the need for syringes or specialized knowledge. This could dramatically reduce animal stress and improve disease prevention. Consequently, it is estimated to contribute to enhanced livestock product quality and extended pet lifespans, potentially yielding economic returns in the hundreds of thousands of dollars annually (AI est.).
Patent Record
APPLICATION NO.
特願2024-510405
REGISTRATION NO.
7487992
FILING DATE
2023/10/20
GRANT DATE
2024/05/13
EXPIRATION DATE
2043/10/20
PATENT HOLDER
国立研究開発法人農業・食品産業技術総合研究機構
Examination History
2024年02月19日
出願審査請求書
2024年02月19日
早期審査に関する事情説明書
2024年03月11日
早期審査に関する通知書
2024年03月12日
拒絶理由通知書
2024年04月09日
意見書
2024年04月09日
手続補正書（自発・内容）
2024年04月23日
特許査定